Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular...

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), crucial for the mevalonate pathway.
• Preclinical studies show statins inhibit cell proliferation and tumor growth.
• Clinical observations suggest statins may decrease cancer-specific mortality.

Purpose of the Study:

• To review the clinical significance of statins in cancer prevention and treatment.
• To discuss the proposed molecular mechanisms underlying statins' anti-cancer effects.
• To address the lack of consensus on statins' specific molecular targets in cancer.

Main Methods:

• Literature review of preclinical and clinical studies on statins and cancer.
• Analysis of proposed mechanisms, including apoptosis induction via mitochondrial pathways.
• Evaluation of studies assessing statin use and mortality in various cancer types.

Main Results:

• Statins demonstrate anti-proliferative and tumor-inhibiting effects in vitro and in animal models.
• Evidence suggests statins can induce tumor-specific apoptosis by suppressing mevalonate pathway intermediates.
• Studies indicate a potential association between statin use and reduced cancer-specific mortality.

Conclusions:

• Statins show promise in cancer prevention and treatment through various molecular mechanisms.
• Further research is needed to clarify the precise molecular targets and optimize clinical application.
• Statins warrant consideration for their potential role in oncology, pending further investigation.